Phase 2 Trial of Triple Combo in Treating Advanced Breast Cancer Opening, Zymeworks Says
News
Zymeworks announced the start of a Phase 2 trial examining its experimental cancer treatment ZW25, in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and the hormone therapy Faslodex (fulvestrant), in ... Read more